Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A, Pereira, Colombia.
Grupo Biomedicina, Fundación Universitaria Autónoma de Las Américas, Pereira, Colombia.
Pain Res Manag. 2020 Jul 16;2020:3891436. doi: 10.1155/2020/3891436. eCollection 2020.
The objective was to determine the trend in the use of opioid analgesics in a cohort of patients diagnosed with and treated for rheumatoid arthritis (RA) in 24 cities in Colombia. This retrospective cohort study included adult patients diagnosed with RA, which was managed in a specialized institution in Colombia between January 2011 and December 2012. The first rheumatology visit was recorded as an index date, and monthly monitoring of the analgesic medication received was performed until December 2017. Sociodemographic variables, the use of opioids, and concomitant prescriptions were evaluated. A total of 1,329 patients diagnosed with and treated for RA were included; they had a mean age of 61.2 ± 11.8 years and were predominantly females ( = 936; 82.9%). A total of 1,129 (84.9%) subjects used opioids for at least one month, and a growing trend, from 13.5% to 21.4%, was observed in patients who received opioids every month throughout a 7-year follow-up of the cohort. In total, 46.7% of the cases used opioids for more than 12 months. The most commonly used opioids were codeine (76.3%) and tramadol (71.1%). All patients received conventional disease-modifying antirheumatic drugs (DMARDs), 85.6% received systemic corticosteroids, 73.9% received nonsteroidal anti-inflammatory drugs, and 15.9% received biological DMARDs. A high proportion of opioid use was shown for pain management in patients with RA, in many cases for more than 12 months, in whom the efficacy and especially safety, related to the risk of dependence, should be monitored.
目的是确定在哥伦比亚 24 个城市的一个类风湿关节炎(RA)患者队列中使用阿片类镇痛药的趋势。这项回顾性队列研究纳入了 2011 年 1 月至 2012 年 12 月期间在哥伦比亚专门机构诊断和治疗的 RA 成年患者。第一次风湿病就诊记录为索引日期,对接受的镇痛药物进行每月监测,直至 2017 年 12 月。评估了社会人口统计学变量、阿片类药物的使用情况和伴随处方。共纳入 1329 例诊断和治疗 RA 的患者;他们的平均年龄为 61.2±11.8 岁,主要为女性(n=936;82.9%)。共有 1129 例(84.9%)患者至少使用了一种阿片类药物 1 个月,在 7 年的队列随访中,每月使用阿片类药物的患者比例从 13.5%增加到 21.4%,呈上升趋势。共有 46.7%的病例使用阿片类药物超过 12 个月。最常使用的阿片类药物是可待因(76.3%)和曲马多(71.1%)。所有患者均接受常规的疾病修饰抗风湿药物(DMARDs)治疗,85.6%接受全身皮质类固醇治疗,73.9%接受非甾体抗炎药治疗,15.9%接受生物 DMARDs 治疗。RA 患者的疼痛管理中显示出高比例的阿片类药物使用,在许多情况下超过 12 个月,应监测其疗效,特别是与依赖风险相关的安全性。